At 9.6% CAGR, Global Cancer Gene Therapy Market Size Estimated to Cross USD 3.99 Billion Value By 2030: Polaris Market Research
February 24, 2023 07:54 ET
|
Polaris Market Research & Consulting LLP
New York, NY, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Polaris Market Research has published a new research report titled “Cancer Gene Therapy Market Share, Size, Trends, Industry Analysis Report, By...
Gene Therapy R&D and Revenue Forecasts 2020-2030
April 14, 2021 05:49 ET
|
ReportLinker
New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Gene Therapy R&D and Revenue Forecasts 2020-2030" -...
Cancer Gene Therapy Market to Reach $2,082.5 Mn, Globally, by 2023
May 08, 2019 10:55 ET
|
Allied Market Research
Portland, OR, May 08, 2019 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global cancer gene therapy market garnered $385.8 million and is likely to accrue a...
Visiongain launches new report on Gene Therapy R&D and Revenue Forecasts 2018-2028
September 05, 2018 12:33 ET
|
Visiongain Ltd
LONDON, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Gene Therapy Market set to Grow at a CAGR of 41.1% in the first half of the forecast period. Visiongain has launched a new pharma report: Gene Therapy...
BioCanCell Announces Company Name Change to Anchiano Therapeutics
August 27, 2018 08:30 ET
|
Anchiano Therapeutics
CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat...
BioCanCell Reports Second Quarter 2018 Financial and Operational Results
August 22, 2018 08:30 ET
|
BioCanCell, Ltd.
CAMBRIDGE, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat...
BioCanCell Announces Completion of $23 Million PIPE Financing
July 03, 2018 08:30 ET
|
BioCanCell, Ltd.
CAMBRIDGE, Mass., July 03, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel...
BioCanCell Reports First Quarter 2018 Financial and Operational Results and Provides Corporate Update
May 15, 2018 08:00 ET
|
BioCanCell, Ltd.
Presented final data from its Phase 2 study of BC-819 for early stage bladder cancer at the 2018 ASCO Genitourinary Cancers Symposium Announced two key hires in clinical development and clinical...
BioCanCell Announces $23 Million PIPE Financing
April 13, 2018 08:00 ET
|
BioCanCell, Ltd.
Financing, led by Shavit Capital, includes U.S. and Israeli investors CAMBRIDGE, Mass., April 13, 2018 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE:BICL), a clinical-stage biopharmaceutical company...
BioCanCell Announces Two New Key Hires in Clinical Development and Clinical Operations
March 07, 2018 08:00 ET
|
BioCanCell, Ltd.
Ronald Knickerbocker, Ph.D. named Senior Vice President of Clinical Development and Data Sciences Sean Daly named Vice President of Clinical Operations CAMBRIDGE, Mass., March 07, 2018 (GLOBE...